Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Oruka Therapeutics, Inc. Develops long-acting antibody therapies for chronic inflammatory and skin diseases.	United States of America	ORKA
Orum Therapeutics, Inc. Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.	South Korea	475830
OSR Holdings, Inc. Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.	United States of America	OSRH
OS Therapies Inc Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.	United States of America	OSTX
Otsuka Holdings Co., Ltd. Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.	Japan	4578
Outlook Therapeutics, Inc. Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.	United States of America	OTLK
Ovid Therapeutics Inc. Developing targeted small molecule therapies for rare neurological diseases and epilepsies.	United States of America	OVID
Ovoca Bio Plc Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).	Ireland	OVXA
Oxford Biomedica PLC A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.	United Kingdom	OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.	United Kingdom	OCTHF